ERBB2 and breast carcinoma: Our previous report indicated that endocrine-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9 overexpress HER-2 [27], suggesting that endocrine-resistant breast cancers are more aggressive than the wild-type MCF-7 cells.